Article Sidebar
Published:
Jun 16, 2022DOI:
10.4314/tjpr.v21i5.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
MFAP2 contributes to the proliferation and motility of lung cancer cells via Wnt/β-catenin pathway
Abstract
Purpose: To measure microfibrillar-associated protein 2 (MFAP2) expression levels in lung cancer and identify its role in lung cancer.
Methods: Immunoblots and PCR were used to determine the expression of MFAP2 in lung cancer cell lines. The effects of MFAP2 on the viability and apoptosis of lung cancer cells were evaluated by CCK-8, colony formation, and flow cytometry (FCM) assays, while wound healing and Transwell assays were used to assess the effects of MFAP2 on the motility and epithelial-mesenchymal transition (EMT) of lung cancer cells. Immunoblot assays were also performed to determine the effect of MFAP2 on the Wnt/β-catenin axis in lung cancer cells.
Results: MFAP2 was highly expressed in lung cancer cells. Depletion of MFAP2 suppressed the viability and stimulated apoptosis in these cells (p < 0.01). In addition, knockdown of MFAP2 suppressed the motility and EMT of lung cancer cells (p < 0.01). MFAP2 mediated the Wnt/β-catenin axis and affected the viability and motility of lung cancer cells.
Conclusion: MFAP2 is a promising target for lung cancer treatment.
